Samsung Bioepis biosimilar Eticovo gets FDA approval

recently, Samsung Bioepiscompany(http:// announcedthat its bio-
pharmaceutical(http://Eticovo (http:// was approved by the u.SFDA(http://the drug is a biosimilar of Amgen and Pfizer-branded drug Enbrel (Enley, generic name: etanercept, inasip) and administered through subcutaneous injections to treat a variety of autoimmune diseases, including: rheumatoid arthritis (RA), polyarthritis of multiple joints and congenital arthritis (JIA, 2 years and older), psilocyander arthritis (PsA), strong spinal inflammation (AS), plaque psoria psilocyanderEticovo is the 19th biosimilar approved by the FDA and the second Enbrel biosimilarNovartis's Suncorp biosimilar Erelzi (Etanercept-szzs) was approved by the FDA in August 2016, making it the first Enbrel biosimilar approved by the agencyAt present, Erelzi is not available in the U.SmarketSands is in legal action with Amin over when it will be available on the U.Smarket, withanalysis of (http:// predicting that the product (http:// could be available in the U.S at any time between 2021 and 2029 But in the European market, both Sands and Baxter/Samsung Bioepis have successfully launched their respective Enbrel biosimilars 　　Enbrel is Amgen's super-heavyweight TNF inhibitor, with Sales in North America run by Pfizer In recent years, biosimilar sales have fallen for the second year in a row, with global sales of $7.126 billion in 2018, down 9.63 percent from 2017 　　The entire European market in Inasip includes: Amin's Enbrel at 55 per cent, Samsung's Benepal i at 38 per cent and Sanders' Elerzi at 7 per cent According to a March report, Benepal's market share in the UK, Scandinavia and Germany was 72%, 53% and 45%, respectively